<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884893</url>
  </required_header>
  <id_info>
    <org_study_id>R18097M</org_study_id>
    <nct_id>NCT04884893</nct_id>
  </id_info>
  <brief_title>Effect of Nitrous Oxide on EEG</brief_title>
  <acronym>HUMANOID</acronym>
  <official_title>The Effect of Nitrous Oxide on EEG, a Randomized, Double-blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our recent preclinical observations suggest that monitoring of slow electroencephalogram&#xD;
      (EEG) oscillations may be used to predict the efficacy of rapid-acting antidepressants such&#xD;
      as ketamine or nitrous oxide. In this project we will carry out critical clinical research on&#xD;
      healthy volunteers and study the effects of nitrous oxide on EEG. Results will be used for&#xD;
      the design of clinical trials on depressed individuals. The project will be done in&#xD;
      collaboration between neuroscientists at the University of Helsinki and clinicians at the&#xD;
      Tampere University Hospital.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Slow wave activity</measure>
    <time_frame>During nitrous oxide administration</time_frame>
    <description>Delta wave in EEG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slow wave activity</measure>
    <time_frame>Following 20 minutes after nitrous oxide administration</time_frame>
    <description>Delta wave in EEG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported psychiatric symptoms</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Symptom Check List 90 (SCL-90) is a self-reported questionnaire measuring psychological stress. Results are normed, meaning that test scores can be compared to Finnish reference values. In this study we measure if there is an increase in self-reported psychiatric symptoms after nitrous oxide administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - anxiety</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported anxiety on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - restlessness</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported restlessness on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - mood elevation</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported mood elevation on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - nausea</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported nausea on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - tension</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported tension on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - uneasiness</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported uneasiness on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - tiredness</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported tiredness on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - numbness</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported numbness on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - dizziness</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported dizziness on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects - agitation</measure>
    <time_frame>Baseline, 20 minutes after nitrous oxide</time_frame>
    <description>Self reported agitation on a 0 (no at all) to 5 (very much) scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nitrous Oxide</condition>
  <condition>Electroencephalography</condition>
  <condition>Anesthetic, Inhalation</condition>
  <arm_group>
    <arm_group_label>Intermittent nitrous oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 minutes of 50% nitrous oxide + 10 min 100% oxygen + 10 min 50% nitrous oxide + 10 min 100% oxygen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous nitrous oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 min 50% nitrous oxide + 20 min 100% oxygen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrous Oxide</intervention_name>
    <description>50% nitrous oxide</description>
    <arm_group_label>Continuous nitrous oxide</arm_group_label>
    <arm_group_label>Intermittent nitrous oxide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. informed consent obtained&#xD;
&#xD;
          2. age between 18 - 40&#xD;
&#xD;
          3. male&#xD;
&#xD;
          4. body mass index 18 - 27&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 or &gt; 40&#xD;
&#xD;
          2. Alcohol Use Disorders Identification Test (AUDIT) &gt;6 points&#xD;
&#xD;
          3. Drug Abuse Screening Test 20 (DAST-20) &gt; 0 points&#xD;
&#xD;
          4. Beck Depression Inventory (BDI) &gt; 11 points&#xD;
&#xD;
          5. Symptom Check List 90 (SCL-90) over mean values of Finnish population in any&#xD;
             dimensions of the SCL-90 or the global severity index&#xD;
&#xD;
          6. Any respiratory disorder including sleep apnea&#xD;
&#xD;
          7. Any heart illness&#xD;
&#xD;
          8. Epilepsy&#xD;
&#xD;
          9. Known vitamin B12 deficiency&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females excluded due to higher risk of nausea and due to menstrual cycle's effect on EEG</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maija-Liisa Kalliom√§ki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Valtonen, MD</last_name>
    <phone>0331164278</phone>
    <email>petra.valtonen@pshp.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maija-Liisa Kalliomaki, PhD</last_name>
      <phone>+358331169424</phone>
      <email>maija-liisa.kalliomaki@pshp.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EEG</keyword>
  <keyword>Slow wave activity</keyword>
  <keyword>Nitrous oxide</keyword>
  <keyword>N-methyl-D-aspartate-receptor blockade</keyword>
  <keyword>Delta wave</keyword>
  <keyword>Self-reported psychiatric symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

